open access

Vol 15, No 2 (2019)
Case report
Published online: 2019-05-17
Get Citation

Nivolumab in the treatment of advanced renal cell carcinoma

Piotr Tomczak, Zuzanna Synowiec
DOI: 10.5603/OCP.2018.0040
·
Oncol Clin Pract 2019;15(2):124-126.

open access

Vol 15, No 2 (2019)
CASE REPORT
Published online: 2019-05-17

Abstract

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody approved for the treatment of advanced and metastatic renal cell carcinoma. Treatment with nivolumab is characterised by favourable toxicity profile. The occurrence of grade 3 and 4 toxicity during the therapy is low. This article describes a medical history of a patient with metastatic renal cell carcinoma treated with nivolumab.

Abstract

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody approved for the treatment of advanced and metastatic renal cell carcinoma. Treatment with nivolumab is characterised by favourable toxicity profile. The occurrence of grade 3 and 4 toxicity during the therapy is low. This article describes a medical history of a patient with metastatic renal cell carcinoma treated with nivolumab.
Get Citation

Keywords

renal cell carcinoma; immunotherapy; nivolumab

About this article
Title

Nivolumab in the treatment of advanced renal cell carcinoma

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 2 (2019)

Article type

Case report

Pages

124-126

Published online

2019-05-17

DOI

10.5603/OCP.2018.0040

Bibliographic record

Oncol Clin Pract 2019;15(2):124-126.

Keywords

renal cell carcinoma
immunotherapy
nivolumab

Authors

Piotr Tomczak
Zuzanna Synowiec

References (10)
  1. Wysocki P, Borkowski T. Nowotwory układu moczowo-płciowego. In: Krzakowski M. ed. Onkologia kliniczna, t. 2. Via Medica , Gdańsk 2015: 751–760.
  2. Escudier B, Porta C, Schmidinger M, et al. ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(Suppl 5): 58–68.
  3. Krawczyk P, Wojas-Krawczyk K. Immunoterapia ukierunkowana na immunologiczne punkty kontroli. In: Wysocki P. ed. Immunoonkologia. ViaMedica , Gdańsk 2016: 47–57.
  4. Motzer R, Escudier B, McDermott D, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
  5. Xu JX, Maher VE, Zhang L, et al. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. 2017; 22(3): 311–317.
  6. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8): 2530–2540.
  7. Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017; 28(8): 2002–2008.
  8. Brahmer J, Lacchetti C, Schneider B, et al. American Society of Clinical Oncology. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018; 36(17): 1714–1768.
  9. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012; 104(2): 93–113.
  10. Escudier B, Sharma P, McDermott D, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017; 72(6): 962–971.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl